177 related articles for article (PubMed ID: 26189598)
1. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ.
Lei L; Liu Q; Liu S; Huan Y; Sun S; Chen Z; Li L; Feng Z; Li Y; Shen Z
Metabolism; 2015 Oct; 64(10):1250-61. PubMed ID: 26189598
[TBL] [Abstract][Full Text] [Related]
2. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
4. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARγ.
Li Y; Tian K; Qin A; Zhang L; Huo L; Lei L; Shen Z; Song H; Feng Z
Eur J Med Chem; 2014 Apr; 76():182-92. PubMed ID: 24583379
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic effects of rice hull smoke extract on glucose-regulating mechanism in type 2 diabetic mice.
Yang JY; Moon E; Nam SH; Friedman M
J Agric Food Chem; 2012 Aug; 60(30):7442-9. PubMed ID: 22803686
[TBL] [Abstract][Full Text] [Related]
8. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
[TBL] [Abstract][Full Text] [Related]
9. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
10. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
[TBL] [Abstract][Full Text] [Related]
11. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.
Deng T; Shan S; Li PP; Shen ZF; Lu XP; Cheng J; Ning ZQ
Endocrinology; 2006 Feb; 147(2):875-84. PubMed ID: 16269451
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
[TBL] [Abstract][Full Text] [Related]
14. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
[TBL] [Abstract][Full Text] [Related]
15. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
[TBL] [Abstract][Full Text] [Related]
16. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
[TBL] [Abstract][Full Text] [Related]
17. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
18. A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
Efanov AM; Barrett DG; Brenner MB; Briggs SL; Delaunois A; Durbin JD; Giese U; Guo H; Radloff M; Gil GS; Sewing S; Wang Y; Weichert A; Zaliani A; Gromada J
Endocrinology; 2005 Sep; 146(9):3696-701. PubMed ID: 15919746
[TBL] [Abstract][Full Text] [Related]
19. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Tsumura Y; Tsushima Y; Tamura A; Hasebe M; Kanou M; Kato H; Kobayashi T
PLoS One; 2017; 12(2):e0172252. PubMed ID: 28207836
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
Moyers JS; Shiyanova TL; Mehrbod F; Dunbar JD; Noblitt TW; Otto KA; Reifel-Miller A; Kharitonenkov A
J Cell Physiol; 2007 Jan; 210(1):1-6. PubMed ID: 17063460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
